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Abstract
OBJECTIVE—Vitamin D has various actions in skeletal muscle. The purpose of this study was to
compare lower limb muscle size and strength in hemodialysis (HD) patients being treated with 1,25-
dihydroxyvitamin D (calcitriol) or a 1,25-dihydroxyvitamin D analog (paricalcitol) to HD patients
who were receiving none.
DESIGN—This was a retrospective cross-sectional study.
SETTING—Outpatient hemodialysis centers.
PATIENTS—HD patients receiving calcitriol or paricalcitol (active vitamin D) for control of
secondary hyperparathyroidism (VitD, n = 49) were compared to HD patients who were not (n = 30).
MAIN OUTCOME MEASURES—Cross-sectional areas (CSA) of thigh and tibialis anterior
muscles by magnetic resonance imaging (MRI), and three measures of strength; three-repetition
maximum (3RM) for knee extension (isotonic), peak torque of knee extensors (isokinetic), and
maximal voluntary contraction (MVC) of the ankle dorsiflexor muscles (isometric).
RESULTS—There were no differences in age, weight, dialysis vintage, or intact parathyroid
hormone levels between the groups, although serum albumin was higher in the VitD group (p <0.05).
Patients in the VitD group had larger thigh muscle CSA (p < 0.05) and were stronger across all
strength measures (p< 0.05) after controlling for age and gender (ANCOVA). When all analyses
were subsequently adjusted for serum albumin concentration, only the difference in 3RM knee
extension strength lost significance. There were no significant differences in any measurements
between patients who received calcitriol or paricalcitol.
CONCLUSION—Treatment with active vitamin D was associated with greater muscle size and
strength in this cohort of HD patients.
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Introduction
Muscle wasting and weakness are common in patients with end-stage renal disease (ESRD)
[1]. Progressive muscle weakness results in significant limitations to physical functioning
[1], which leads to disability, loss of independence and diminished quality of life [2], all of
which are associated with increased morbidity and mortality in the ESRD population [3].
Muscle wasting in ESRD has multiple causes including malnutrition, inflammation, uremia,
and metabolic disturbances, and likely, vitamin D deficiency [4]. Secondary
hyperparathyroidism (SHPT) develops in chronic kidney disease (CKD) and ESRD in response
to disruptions in the homeostatic control of parathyroid hormone (PTH) secretion related to
alterations in serum phosphorous, calcium (Ca2+), and declining 1,25 dihydroxyvitamin D
(1,25 (OH)2D) levels, which occur with diminishing renal function. Although the molecular
actions of vitamin D in skeletal muscle are well known, the current focus of vitamin D treatment
in ESRD is the prevention and treatment of SHPT and its effects on bone metabolism and tissue
calcification, as outlined in the current Kidney Disease Quality Outcomes Initiatives (K/DOQI)
guidelines [5].
Vitamin D plays an essential role in muscle growth and development [6] and in regulating
muscle contractility [7]. Numerous studies in animals and humans have demonstrated the
effects of vitamin D deficiency on various aspects of muscle cell function [8-11]. Vitamin D
deficiency is associated with decreased muscle size [12-14] and strength [15,16], particularly
of the large extensor and flexor muscles of the lower limbs [16], essential for functional
mobility, and with reduced physical function and increased falls in the elderly [15]. There is
evidence that these deficits can be improved by vitamin D supplementation [16].
A few studies have examined the effects of vitamin D treatment on muscle function in patients
with ESRD [17-20]. Although collectively these studies provide evidence that treatment with
vitamin D may have a positive effect on various aspects of muscle function in patients with
ESRD, small sample size, poorly described study designs, and vague descriptions of clinical
outcomes related to strength make it difficult to draw any firm conclusions or to generalize the
results. The goal of this preliminary investigation was to determine whether vitamin D
treatment for SHPT was associated with muscle size and strength or physical performance in
patients receiving dialysis therapy.
Methods
Subjects and study design
Subjects in this cross-sectional study were initially recruited into the NEXT (Nandrolone and
Exercise Trial) Study [21]. Briefly, men and women undergoing maintenance hemodialysis
three times per week at the outpatient dialysis units at San Francisco General Hospital, the
UCSF-Mount Zion Medical Center, and the San Francisco VA Medical Center were eligible
to participate in the study. Inclusion criteria included adequate dialysis delivery with Kt/V ≥
1.2 and good compliance with dialysis treatment (i.e., not missing more than two dialysis
treatments in the month prior to enrollment). Patients were excluded if they had been on dialysis
for less than three months; if they had reasons to be in a catabolic state (including HIV with
opportunistic infection in the last three months, malignancy, or infection requiring intravenous
antibiotics within two months prior to enrollment); were unable to give informed consent; were
active intravenous drug users; or had contraindications to resistance exercise training such as
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myocardial infarction within six months, active angina, uncompensated congestive heart
failure, or orthopedic or musculoskeletal limitations. Informed consent was obtained from all
participants, and the study was approved by the Committee on Human Research at the
University of California, San Francisco, and the Research & Development Committee of the
San Francisco VA Medical Center.
Group Assignment
Subjects were categorized into two groups; those receiving either 1,25 (OH)2D (calcitriol), or
an analog (paricalcitol) at the time of baseline assessment, and those who were not.
Clinical Measures
Laboratory results of interest were obtained from the most recent routine monthly laboratory
tests from the dialysis units. Serum albumin was measured by dye-binding bromocresol green,
except in 17 subjects from the San Francisco VA Medical Center where serum albumin is
measured by bromocresol purple and corrected accordingly [22]. In addition, the most recent
single-pool Kt/V values were obtained from the patients’ dialysis charts.
Muscle size
Measurement of muscle size was performed on a non-dialysis day. Thigh and tibialis anterior
muscle size were measured using magnetic resonance imaging (MRI). Proton T1-weighted
axial images of the thigh were acquired at 1.5T (Siemens, Magnetom Vision Systems) using
the body coil for the thigh muscles and the extremity coil for the calf muscles (tibialis anterior).
The right lower limb was studied except in cases where there was hardware or previous injury
that appeared to distort the anatomy of the right limb (one subject). Subjects were studied in a
supine position, and the grid for the transverse slices was centered at the midpoint between the
kneecap and the femoral head for the thigh images and at the midpoint between kneecap and
ankle for the calf images (tibialis anterior compartment). The image parameters were as
follows: echo time of 14 ms, field of view equal to 210 mm2, matrix equal to 256 × 256, slice
thickness of 8 mm, 15 slices. These parameters were selected to optimize differences in signal
intensity between contractile (muscle) and noncontractile (e.g., fat) tissue. Before analysis, the
15 slices were arranged anatomically, and the single slice with the largest muscle area was
selected for full analysis. A customized software program written in IDL (Research Systems,
Inc., Boulder, CO) allowed for the separate quantification of contractile and noncontractile
components of the muscle area as previously described [1]. Each image was analyzed three
times, and the average quadriceps, hamstring, and tibialis anterior muscle cross-sectional areas
were recorded.
Muscle Strength
Isotonic strength of the knee extensor muscles was measured using ankle weights. A three-
repetition maximum (3RM) was determined as the maximum weight that could be lifted three
times with good form. 3RM was used rather than 1RM because of concerns about tendon
injuries in this population [23].
Isokinetic strength of the knee extensor and flexors was tested using a computerized
dynamometer (Cybex Inc, Ronkonkoma, NY). Patients were positioned in the chair, and the
knee joint was aligned with the axis of rotation of the dynamometer. Patients performed five
maximal knee extension repetitions with the right lower limb at 90°/sec, and fifteen repetitions
at both 120 and 180°/sec. The peak torque was recorded at each angular velocity for each limb.
Isometric maximum voluntary contraction (MVC) of the ankle dorsiflexor muscles (tibialis
anterior) of the right lower limb was performed with patients in a seated position with the knee
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fixed at ~ 170° of extension and the foot positioned (ankle angle 120°) against a force
transducer. The signal from the force transducer was amplified, converted to digital signal and
displayed using Labview Software (National Instruments, Austin, TX). Three MVCs (3-5 sec
each) were performed with two minutes rest between contractions. The greatest force from the
three MVCs was recorded [1].
Physical Performance
Patients were timed to the nearest hundred of a second while walking 20 feet at their usual pace
and as fast as possible. Subjects were also timed while walking up one flight of stairs, while
rising from a chair five consecutive times without stopping, and during the timed up and go
test, in which the subject rises from a chair, walks three meters, turns around walks back to the
chair and sits down. All tests were performed twice, and the best time was recorded.
Physical activity
Physical activity was measured using three-dimensional accelerometers (TriTrac R3D;
Professional Products, Inc., Madison, WI) worn for one week [24].
Self-Reported Functioning
Self-reported functioning was measured using the Physical Functioning (PF) score of the
Medical Outcomes Study 36-Item Short Form health status questionnaire (SF-36) [25] and the
adjusted activity score (AAS) of the Human Activity Profile (HAP) [26]. The questions that
make up the PF scale of the SF-36 ask individuals to characterize their degree of limitation in
performing 10 activities as not limited at all, limited a little, or limited a lot. The HAP consists
of a list of 94 activities, and patients are asked to report whether they still do the activity, no
longer do the activity, or never did the activity.
Statistical Analyses
Data are reported as the mean ± standard error of the mean, except for non-normally distributed
data which are reported as the median, minimum and maximum. Clinical characteristics of
patients receiving either calcitriol or paricalcitol were compared to those who were not
receiving a vitamin D preparation by one-way analysis of variance (ANOVA) or Mann-
Whitney U tests where appropriate. One-way analyses of covariance (ANCOVA) were used
to test for differences between the two groups in muscle size, strength, tests of physical
performance, and activity levels. Age and gender, both important determinants of muscle size
and strength, were used as covariates. In addition, clinical characteristics found to be distributed
unequally between groups, such as serum albumin concentration, diabetes mellitus, and
peripheral vascular disease, were also considered as covariates to test for independent effects
on the variables of interest. In order to compare the magnitude of the association of vitamin D
receipt or non-receipt to the magnitude of the association of age, sex, and serum albumin on
muscle size and strength, we also performed multivariable linear regression analysis with
muscle size and strength as the outcome variables. Finally, to test whether there were any
differences between the group of patients who were receiving calcitriol and the group receiving
paricalcitol, ANCOVA was used to compare muscle size, strength, physical performance,
physical activity and self-reported functioning; adjusting for age and/or gender as described
above. Differences were considered statistically significant if the two-tailed p-value was less
than 0.05. Analyses were performed using SPSS 12.0.2 (SPSS Inc., Chicago, IL).
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Two hundred and seventy-eight hemodialysis patients were screened for the NEXT study, of
which one hundred and sixty were found eligible, out of which seventy-nine men and women
agreed to participate [21]. Of those, 49 were receiving intravenous doses of 1,25 (OH)2 vitamin
D (calcitriol, n = 26, median dose; 3.0 mcg, min dose; 0.5 mcg – max dose; 9 mcg) or a 1,25
(OH)2 vitamin D analog (paricalcitol, n = 23, median dose; 9 mcg, min dose; 0.5 mcg – max
dose; 42 mcg) one to three times weekly. The duration of treatment is not known. The remaining
30 subjects were receiving no vitamin D or vitamin D analog at the time of recruitment,
although we have no information as to whether any of these subjects had received any form of
active vitamin D at any point previous to recruitment. Subject clinical characteristics are shown
in Table 1. There were no statistically significant differences in age, gender, ethnicity or race
distribution, comorbidities, dialysis vintage or anthropometric measurements between the two
groups. Although the differences were not significant, there were slightly more patients with
diabetes in the group not receiving vitamin D and more patients with peripheral vascular disease
in the group that was receiving treatment with vitamin D. All subjects dialyzed three times per
week and subjects in both groups were well dialyzed [27]. There were no significant differences
in standard blood chemistry values including intact PTH levels between the two groups (Table
1). Most subjects were adequately nourished, but the mean serum albumin level was lower (P
= 0.04) in those patients who were not receiving any vitamin D (Table 1). As a result, serum
albumin level was entered as a covariate in the analyses of the outcomes of interest. Because
each subject did not undergo every test, results in tables are accompanied by the number of
subjects in each group for whom data are available.
Muscle Size
The results of MRI analyses of the thigh and tibialis anterior muscles are shown in Table 2.
Both age (P = 0.003) and gender (P = 0.001) were significant predictors of thigh muscle size
(Table 3). Nevertheless, total thigh muscle cross-sectional area was greater (P = 0.02) in the
group of patients receiving active vitamin D (calcitriol or paricalcitol) after adjusting for both
age and gender. There was no significant difference in the size of the tibialis anterior muscle
in patients receiving active vitamin D after adjusting for age and gender. Adjustment for serum
albumin concentration, diabetes mellitus, or peripheral vascular disease had no significant
effect on either thigh or tibialis anterior muscle size.
Muscle Strength Measures
Patients receiving active vitamin D were stronger in nearly all strength measures compared to
patients who were not receiving any form of vitamin D (Table 2). Further, the differences
remained significant after adjusting for the effects of age and gender (Table 3). Patients
receiving active vitamin D had greater mean strength of the knee extensors (P = 0.04) after
adjusting for age (P = 0.05) and gender (P = 0.001). However, when serum albumin level (P
= 0.02) was added to the ANCOVA model, both the effects of age (P = 0.06) and vitamin D
group (P = 0.09) became non-significant (Table 3). Addition of diabetes mellitus or peripheral
vascular disease did not substantively alter the results (data not shown).
In the case of isokinetic strength, patients receiving active vitamin D produced greater peak
torque in knee extension (Table 2) at angular velocities of 90°/second (P = 0.02) and 120°/
second (P = 0.04) after adjusting for age and gender (Table 3). There was no significant effect
at 180°/second (P = 0.11) (Table 2). There was no effect of adjustment for serum albumin level,
diabetes mellitus, or peripheral vascular disease on any measure of isokinetic strength.
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Patients receiving active vitamin D produced greater isometric force during MVC of the ankle
dorsiflexors (P = 0.03) (Table 2) after controlling for the effect of gender. There were no effects
of adjustment for age or serum albumin on isometric strength of the ankle dorsiflexors (Table
3).
Physical Performance, Physical Activity, and Self-Reported Functioning Measures
There were no differences in any of the physical performance tests between patients who were
receiving active vitamin D and those who were not (Table 2). Similarly, there were no
significant differences in daily physical activity level measured by accelerometry, or
differences in self reported functioning on the PF scale of the SF-36 (Table 2). However, self-
reported functioning was reported to be modestly better on the AAS of the HAP questionnaire
by subjects who were receiving active vitamin D (P = 0.05) compared to those who were not,
after adjusting for age. There was no effect of either gender or serum albumin or selected
comorbidities.
Multivariable Linear Regression
Examination of linear regression models including the same predictor variables selected in
ANCOVA (Table X) shows that, in general, the magnitude of the vitamin D association is not
as great as the effect of gender. However, the vitamin D association is comparable to or greater
than that of serum albumin concentration or 10 years of age, depending on the specific strength
or size variable.
Comparisons between Active Vitamin D Derivatives
To determine whether there was evidence for a differential effect of paricalcitol on muscle size
or function, patients receiving paricalcitol were compared to those receiving calcitriol. There
were no differences in thigh muscle CSA or tibialis anterior muscle CSA between patients who
were receiving calcitriol or paricalcitol. Further there were no differences in any of the strength,
physical performance, physical activity or self-reported functioning measures (Table 4)
Discussion
The results of the present study suggest that hemodialysis patients who receive active vitamin
D treatment (calcitriol or the analog paricalcitol) for the control of SHPT have larger muscle
size and increased strength compared to similar patients on hemodialysis not receiving active
vitamin D. Patients receiving active vitamin D were stronger across two different muscle
groups and several types of strength measures including isotonic, isokinetic and isometric
strength, and had larger thigh muscle cross-sectional area. This is not completely unexpected
since vitamin D plays essential roles in regulating muscle contractility [7] and muscle growth
[6]. Renal failure results in abnormalities in vitamin D metabolism due to the decline in
proximal tubular production of 1α-hydroxylase. This results in marked declines in circulating
levels of 1,25(OH)2D. Studies in humans show that vitamin D deficiency is associated with
muscle weakness and atrophy [16,28,29]. At the cellular level, vitamin D deficiency impairs
intracellular calcium kinetics and muscle cell contractility [8,9], mitochondrial metabolism
[10,11] and protein synthesis [12,13]. Treatment with vitamin D corrects these impairments
[14,30] as well as restoring strength and improving balance in vitamin D deficient humans
[16,29,31]. Despite the fact that vitamin D deficiency is associated with muscle loss [12,13]
and weakness [16,28,29], which may contribute to the significant muscle atrophy, weakness,
and widespread disability experienced by patients with ESRD, the current focus of vitamin D
treatment for the control of SHPT, as outlined in the current K/DOQI guidelines [5], is on
measuring its effects on bone metabolism and tissue calcification.
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A few studies have examined the effects of vitamin D treatment on muscle and muscle function
in patients with ESRD [17-20]. Although the sample sizes of these studies are quite small (n
= 8 to 27), collectively they lend support to our observation that ESRD patients who receive
treatment with active vitamin D for the treatment of SHPT have larger muscle size and greater
strength. Other studies have examined the effects of vitamin D in muscle from a metabolic
perspective. Skeletal muscle is the major site of insulin-stimulated glucose uptake and the
primary tissue involved in insulin resistance. Insulin resistance is a common feature of ESRD,
and an independent predictor of cardiovascular death in hemodialysis patients [32]. However,
treatment with 1,25 dihydroxyvitamin D significantly improves insulin sensitivity in severely
insulin resistant hemodialysis patients [33] and has been shown to be independently associated
with reduced risks for cardiovascular [34] and all-cause death [35] in the hemodialysis
population. Taken together, these studies suggest that vitamin D may have multiple effects in
skeletal muscle, regulating processes that contribute to muscle anabolism, metabolism, and
function, with far reaching effects on survival.
Although we hypothesized that patients who were receiving active vitamin D would have better
physical performance due to the greater strength of the knee extensor and ankle dorsiflexor
muscles, there were no significant differences between the two groups in any of the physical
performance tests. This may be due to the large degree of inter-subject variability in the
measurements. Low muscle strength is often associated with poorer physical function in the
elderly [36], a population similar to the ESRD population with regard to comorbidity and
disability rates. However, a large population-based study of performance-based measures of
muscle function in the elderly revealed that subjective health and psychological factors explain
a significantly larger proportion of the variability in the complex measures of gait speed and
timed chair stands than direct measures of strength [37]. Further, in hemodialysis patients, there
is evidence that at least one additional dialysis-related factor, dialysis adequacy (Kt/V), is also
an important determinant of physical performance [38], and other factors such as fluid volume
status, anemia, inflammation and chronic fatigue may have effects as well. So it is possible
that variability due to these and other unmeasured subjective health and psychological factors
prevented discrimination between the groups in the performance measures of the present study.
There are several limitations to this study. First, this was a retrospective cross-sectional
analysis. From the available data we sought only to determine whether there were differences
in thigh muscle size, strength, or in physical performance measures between patients who were
receiving any dose of active vitamin D at the time of testing and those who were not. Therefore,
a causal relationship cannot be established. Second, we do not know the specific reasons for
the decisions to treat or not treat individual patients with vitamin D. We generally assume that
these ESRD patients were being treated with active vitamin D for secondary
hyperparathyroidism. However, PTH level is not the only determining factor for the decision
to treat or not treat with active vitamin D. Calcium and phosphorous levels were similar
between the groups, but nevertheless hypercalcemia and hyperphosphatemia are possible
reasons for the non-use of active vitamin treatment. In addition, we have no information as to
whether patients who were not receiving active vitamin D at the time of testing had previously
received treatment, nor do we know the duration of active vitamin D treatment for any of the
patients who were receiving treatment at the time of testing. Also, we did not measure
circulating levels of 1,25(OH)2D, due in large part to the limitations of assays to accurately
measure the levels of 1,25(OH)2D analogs. However, it is likely that most patients not receiving
treatment with active vitamin D for SHPT were 1,25(OH)2D deficient. In general, serum levels
of 1,25(OH)2D decrease as renal mass declines, with serum concentrations of 1,25(OH)2D
reported to be positively correlated with GFR [39] and creatinine clearance [40-42].
Nevertheless, we acknowledge that variability in extrarenal 1,25(OH)2D production make it
impossible to assume that 1,25(OH)2D deficiency is present in every ESRD patient not treated
with active vitamin D. However, potential misclassifications from inclusion of patients recently
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treated with vitamin D derivatives and patients who may not be vitamin D deficient in the non-
vitamin D-receiving group would tend to minimize rather than accentuate associations between
active vitamin D treatment and muscle strength and size.
Although there are reports that other 1,25 (OH)2D analogs may have selectively different
actions in cultured skeletal muscle cells there is no published information specific to the actions
of paricalcitol in skeletal muscle. Nevertheless, we compared muscle size, muscle strength,
and physical performance measures among patients who were receiving active vitamin D
treatment, and found no significant differences between patients who were receiving calcitriol
compared to those receiving paricalcitol. Though, we cannot rule out the possibility that
paricalcitol could have selectively-altered actions in skeletal muscle, we had little statistical
power to address this question in the present study.
Although the results of this study must be considered preliminary, the consistency of the
relationship among active vitamin D treatment, muscle size and multiple measures of strength
lends support to the association. While a causal relationship cannot be established based on
our results, our observations have biological plausibility. Disability due to low physical
functioning is widespread and contributes greatly to diminished quality of life in patients with
ESRD. Treatment with active vitamin D was associated with greater muscle size and strength
in this cohort of HD patients, suggesting that vitamin D may play a role in the preservation of
muscle size and strength in this population.
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Figure 1. Difference in Thigh Muscle Cross-sectional Area (CSA)
Bars represent thigh muscle CSA in cm2, measured by magnetic resonance imaging. Subjects
were categorized into two groups; those receiving either 1,25 (OH)2D (calcitriol), or an analog
(paricalcitol) (black bar), and those who were not (light bar) at the time of baseline assessment
of the NEXT study [21]. Statistical significance is * P<0.05 by ANCOVA, after adjusting for
age and gender. Error bars represent the SEM.
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Figure 2. Differences in Isokinetic Strength of Knee Extensors
Bars represent peak torque at 90, 120, and 180°/sec knee extension angular velocities measured
in Newton meters (N ∙ m) by computerized dynamometry (Cybex Inc, Ronkonkoma, NY).
Subjects were categorized into two groups; those receiving either 1,25 (OH)2D (calcitriol), or
an analog (paricalcitol) (black bars), and those who were not (light bars) at the time of baseline
assessment of the NEXT study [21]. Statistical significance is * P<0.05 by ANCOVA, after
adjusting for age and gender. Error bars represent the SEM.
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